title: [Hepatitis B (acute and chronic)].
authors.affiliation: Medizinische Poliklinik, Universitätsspital Zürich. urania.kolyvanos@usz.ch
authors.forename: U
authors.initials: U
authors.lastname: Kolyvanos Naumann
authors.forename: L
authors.initials: L
authors.lastname: Käser
authors.forename: W
authors.initials: W
authors.lastname: Vetter
mesh_terms: D000208:Acute Disease; D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000175:diagnosis / Q000276:immunology / Q000401:mortality / Q000517:prevention & control / Q000628:therapy; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D017325:Hepatitis B Vaccines / Q000008:administration & dosage; D006513:Hepatitis B e Antigens / Q000032:analysis; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000276:immunology / Q000401:mortality / Q000517:prevention & control / Q000628:therapy; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D063065:Organophosphonates; D011379:Prognosis; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors; D013997:Time Factors
chemical_list: D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D006513:Hepatitis B e Antigens; D016898:Interferon-alpha; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; C053001:adefovir; D000225:Adenine
vernacular_title: Hepatitis B (akut und chronisch).